SCHEMBL16909697

SCHEMBL16909697

Cc1nc2ccc(-c3ccc([C@H]4CC[C@H](C(=O)O)CC4)nc3)cn2c1Cc1ccccc1OC(F)F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.38
SLC2A1 P11166 3/20 0.36
DGAT1 O75907 2/20 0.34
TNF P01375 1/20 0.33
MCHR1 Q99705 1/20 0.33
EPHB3 P54753 2/20 0.33
FFAR4 Q5NUL3 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
RIPK1 Q13546 2/20 0.32
MAP3K7 O43318 2/20 0.32
TAB1 Q15750 2/20 0.32
PPARD Q03181 2/20 0.32
IGF1R P08069 1/20 0.32
PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16909695 1.00 ALKBH1 (0.38) ALKBH1SLC2A1DGAT1TNFMCHR1
SCHEMBL16909685 0.92 ALKBH1 (0.37) ALKBH1SLC2A1TNFMCHR1PDE4A
SCHEMBL16909707 0.92 ALKBH1 (0.37) ALKBH1SLC2A1TNFMCHR1PDE4A
SCHEMBL16909556 0.92 ALKBH1 (0.38) ALKBH1SLC2A1DGAT1TNFMCHR1
SCHEMBL16909558 0.92 ALKBH1 (0.38) ALKBH1SLC2A1DGAT1TNFMCHR1
SCHEMBL16909815 0.92 ALKBH1 (0.38) ALKBH1SLC2A1DGAT1TNFMCHR1
Ammonia Solution, Strong SCHEMBL16909655 0.88 ALKBH1 (0.39) ALKBH1SLC2A1TNFMCHR1EPHB3
SCHEMBL16909486 0.86 ALKBH1 (0.37) ALKBH1SLC2A1TNFEPHB3PDE4D
Potassium SCHEMBL16909490 0.86 ALKBH1 (0.37) ALKBH1SLC2A1TNFEPHB3PDE4D
SCHEMBL16909640 0.86 ALKBH1 (0.41) ALKBH1SLC2A1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US claimed
EP-2872508-B1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-08-29 EP disclosed
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US disclosed
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity UCB Biopharma SPRL a corporation 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, IL1A ALKBH1 4341/4885SLC2A1 3939/4885DGAT1 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.